Literature DB >> 18275089

Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases.

Petr Niederhafner1, Milan Reinis, Jaroslav Sebestík, Jan Jezek.   

Abstract

Glycopeptide dendrimers containing different types of tumor associated-carbohydrate antigens (T(N), TF, sialyl-T(N), sialyl-TF, sialyl-Le(x), sialyl-Le(a) etc.) were used in diagnosis and therapy of different sorts of cancer. These dendrimeric structures with incorporated T-cell epitopes and adjuvants can be used as antitumor vaccines. Best results were obtained with multiantigenic vaccines, containing, e.g. five or six different TAAs. The topic of TAAs and their dendrimeric forms at molecular level are reviewed, including structure, syntheses, and biological activities. Use of glycopeptide dendrimers as antiviral vaccines against HIV and influenza is also described. Their syntheses, physico-chemical properties, and biological activities are given with many examples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275089     DOI: 10.1002/psc.1011

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  10 in total

1.  Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.

Authors:  Mylène A Carrascal; Paulo F Severino; M Guadalupe Cabral; Mariana Silva; José Alexandre Ferreira; Fernando Calais; Hermínia Quinto; Cláudia Pen; Dário Ligeiro; Lúcio Lara Santos; Fabio Dall'Olio; Paula A Videira
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

2.  Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.

Authors:  Raymond P Brinãs; Andreas Sundgren; Padmini Sahoo; Susan Morey; Kate Rittenhouse-Olson; Greg E Wilding; Wei Deng; Joseph J Barchi
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

Review 3.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

Review 4.  Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.

Authors:  Piper A Rawding; Jiyoon Bu; Jianxin Wang; Da Won Kim; Adam J Drelich; Youngsoo Kim; Seungpyo Hong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-08-19

5.  MAP dendrimer elicits antibodies for detecting rat and mouse GH-binding proteins.

Authors:  Roberto M Aguilar; Frank J Talamantes; Juan J Bustamante; Jesus Muñoz; Lisa R Treviño; Andrew O Martinez; Luis S Haro
Journal:  J Pept Sci       Date:  2009-02       Impact factor: 1.905

Review 6.  Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.

Authors:  Matthew Black; Amanda Trent; Matthew Tirrell; Colleen Olive
Journal:  Expert Rev Vaccines       Date:  2010-02       Impact factor: 5.217

Review 7.  Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking.

Authors:  João Conniot; Joana M Silva; Joana G Fernandes; Liana C Silva; Rogério Gaspar; Steve Brocchini; Helena F Florindo; Teresa S Barata
Journal:  Front Chem       Date:  2014-11-26       Impact factor: 5.221

8.  Synthesis of G0 aminopolyol and aminosugar dendrimers, controlled by NMR and MALDI TOF mass spectrometry.

Authors:  Mikołaj A Pyziak; Grażyna Bartkowiak; Łukasz Popenda; Stefan Jurga; Grzegorz Schroeder
Journal:  Des Monomers Polym       Date:  2016-10-14       Impact factor: 2.650

Review 9.  Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.

Authors:  Alan Kirwan; Marta Utratna; Michael E O'Dwyer; Lokesh Joshi; Michelle Kilcoyne
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

10.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.